Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31590664 | 0.85 | TSHR (0.48) | TSHRALOX15CFTRCA2CA4 | |
| SCHEMBL31590628 | 0.82 | TSHR (0.46) | TSHRALOX15CFTRCA2CA4 | |
| SCHEMBL806050 | 0.81 | TSHR (0.67) | TSHRALOX15CFTRCA2CA4 | |
| SCHEMBL18486579 | 0.80 | MEN1 (0.41) | TSHRCFTRCA2CA4CA5A | |
| SCHEMBL18486535 | 0.80 | MEN1 (0.41) | TSHRCFTRCA2CA4CA5A | |
| SCHEMBL18486534 | 0.80 | MEN1 (0.41) | TSHRCFTRCA2CA4CA5A | |
| SCHEMBL18486575 | 0.80 | MEN1 (0.41) | TSHRCFTRCA2CA4CA5A | |
| SCHEMBL4878268 | 0.80 | SOAT2 (0.47) | TSHRALOX15 | |
| SCHEMBL4878263 | 0.80 | SOAT2 (0.47) | TSHRALOX15 | |
| SCHEMBL31590883 | 0.80 | SOAT2 (0.47) | TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040637-A | Organic phosphonic acid polymer flame retardant, and preparation method and application thereof | 威海海润新材料科技有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-3013424-B1 | LSD INHIBITORS FOR MODULATING CANCER STEM CELLS | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2024-09-25 | — | — | EP | disclosed |
| WO-2021195723-A1 | \"METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS\ | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2021-10-07 | — | — | WO | disclosed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | disclosed |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2021-04-29 | — | — | US | disclosed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20190262377-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-08-29 | — | — | US | disclosed |
| US-10220053-B2 | Methods and compositions for modulating cancer stem cells | UNIVERSITY OF CANBERRA (AU) | 2019-03-05 | — | — | US | disclosed |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| EP-3185858-A1 | COMPOSITIONS FOR MODULATING CANCER STEM CELLS AND USES THEREFOR | University of Canberra (AU) | 2017-07-05 | — | — | EP | disclosed |
| US-20160143938-A1 | Methods and compositions for modulating cancer stem cells | EpiAxis Therapeutics Pty Ltd. (AU) | 2016-05-26 | — | — | US | disclosed |
| EP-3013424-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | University of Canberra (AU) | 2016-05-04 | — | — | EP | disclosed |
| WO-2016029262-A1 | COMPOSITIONS FOR MODULATING CANCER STEM CELLS AND USES THEREFOR | UNIVERSITY OF CANBERRA (AU) | 2016-03-03 | — | — | WO | disclosed |
| WO-2014205511-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | UNIVERSITY OF CANBERRA (AU) | 2014-12-31 | — | — | WO | disclosed |
| US-20120108500-A1 | Compositions and Methods for Modulating Immunodeficiency Virus Transcription | THE J. DAVID GLADSTONE INSTITUTES | 2012-05-03 | — | — | US | disclosed |
| WO-2012047852-A2 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNODEFICIENCY VIRUS TRANSCRIPTION | THE J. DAVID GLADSTONE INSTITUTES (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | TSHR 4333/4885ALOX15 2897/4885CFTR 4754/4885 |
| US-20190262377-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | TSHR 4190/4885ALOX15 2605/4885CFTR 4159/4885 |
| US-20160143938-A1 | Methods and compositions for modulating cancer stem cells | BMI1, KDM1B, KDM6B | TSHR 4190/4885ALOX15 2605/4885CFTR 4159/4885 |
| US-10220053-B2 | Methods and compositions for modulating cancer stem cells | BMI1, KDM1B, KDM6B | TSHR 4190/4885ALOX15 2605/4885CFTR 4159/4885 |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | PDCD1, CD274, PDCD1LG2 | TSHR 1775/4885ALOX15 364/4885CFTR 4841/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | TSHR 4333/4885ALOX15 2897/4885CFTR 4754/4885 |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | TSHR 4190/4885ALOX15 2605/4885CFTR 4159/4885 |
| US-20120108500-A1 | Compositions and Methods for Modulating Immunodeficiency Virus Transcription | KDM3B, DNMT3B, KDM1B | TSHR 4628/4885ALOX15 2964/4885CFTR 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.